Table 2.
Demographic and clinical characteristics of 1-year survivors and non-survivors undergoing liver transplantation for hepatocellular carcinoma.
| Demographic and Clinical Characteristics | Survivors at 1 Year (n = 112) | Non-Survivors at 1 Year (n = 15) | p-Value |
|---|---|---|---|
| Female gender—n (%) | 20 (17.9) | 0 | 0.13 |
| Age (years)—median (P25–P75) | 58 (52–62) | 56 (53–62) | 0.84 |
| Age of liver donor (years)—median (P25–P75) | 52 (36–63) | 62 (49–72) | 0.02 |
| ABO blood type—n (%) | |||
| A | 53 (47.3) | 6 (40.0) | 0.87 |
| B | 9 (8.0) | 2 (13.3) | |
| O | 45 (40.2) | 6 (40.0) | |
| AB | 5 (4.5) | 1 (6.7) | |
| Child-Pugh score—n (%) | |||
| A | 54 (48.2) | 10 (66.7) | 0.41 |
| B | 35 (31.3) | 3 (20.0) | |
| C | 23 (20.5) | 2 (13.3) | |
| MELD score—median (P25–P75) | 15 (11–18) | 15 (15–18) | 0.44 |
| Inside Milan criteria previously to LT—n (%) | 107 (95.5) | 14 (93.3) | 0.54 |
| Inside Milan criteria after LT—n (%) | 94 (83.9) | 11 (73.3) | 0.16 |
| Serum AFP (ng/dL)—median (P25–P75) | 8.0 (4.0–32.0) | 12.0 (4.8–164.9) | 0.42 |
| Portal hypertension—n (%) | 78 (69.6) | 11 (73.3) | 0.99 |
| Multinodular tumor—n (%) | 34 (30.4) | 5 (33.3) | 0.77 |
| Nodule size (cm)—median (P25–P75) | 3.0 (2.0–3.5) | 3.2 (1.7–4.6) | 0.83 |
| Degree of tumor differentiation—n (%) | |||
| Well | 84 (75.0) | 12 (80.0) | 0.55 |
| Moderate | 25 (22.3) | 2 (13.3) | |
| Poor | 3 (2.7) | 1 (6.7) | |
| Infiltration—n (%) | 36 (32.1) | 4 (26.7) | 0.77 |
| Microvascular invasion—n (%) | 24 (21.4) | 3 (20.0) | 0.99 |
| Macrovascular invasion—n (%) | 6 (5.4) | 0 | 0.99 |
| Treatment prior to LT—n (%) | 61 (54.1) | 10 (66.7) | 0.42 |
| Transplantation technique—n (%) | |||
| By-pass | 43 (38.4) | 6 (40.0) | 0.99 |
| Piggy back | 69 (61.6) | 9 (60.0) | |
| Serum MDA (nmol/mL)—median (P25–P75) | 2.95 (2.33–4.01) | 3.66 (3.39–4.62) | 0.02 |
MELD = model for end-stage liver disease; AFP = alpha-fetoprotein; MDA = malondialdehyde.